ライフサイエンスコーパス: ribavirin

1 aged <12 years is pegylated interferon plus ribavirin.

2 of response to treatment with sofosbuvir and ribavirin.

3 extended treatment duration and addition of ribavirin.

4 tocol could be observed and was inhibited by ribavirin.

5 , ruzasvir, and uprifosbuvir with or without ribavirin.

6 nt-experienced with pegylated interferon and ribavirin.

7 that do not require IFN and may not require ribavirin.

8 f elbasvir and grazoprevir, with and without ribavirin.

9 f elbasvir and grazoprevir, with and without ribavirin.

10 nfection who were treated with a PEG-IFN and ribavirin.

11 nts treated for short durations with SOF and ribavirin.

12 12), and safety of ledipasvir/sofosbuvir +/- ribavirin.

13 ot transversion mutations in the presence of ribavirin.

14 lls that were left untreated or treated with ribavirin.

15 sofosbuvir and velpatasvir with and without ribavirin.

16 th Pegylated interferon-alpha (Peg-IFN) plus ribavirin.

17 ombitasvir, paritaprevir, and ritonavir plus ribavirin.

18 ere given sofosbuvir and velpatasvir without ribavirin.

19 ome patients were offered a second course of ribavirin.

20 hieved SVR12 after 8 weeks of treatment with ribavirin.

21 altered RSV susceptibility to palivizumab or ribavirin.

22 ponse (SVR) of 60% with pegylated-interferon/ribavirin.

23 d tested their sensitivity to sofosbuvir and ribavirin.

24 weeks of grazoprevir-elbasvir combined with ribavirin.

25 merase failed to make the virus resistant to ribavirin.

26 unosuppressive therapy and/or treatment with ribavirin.

27 antiviral activity against HEV when added to ribavirin.

28 ral clearance in mice that were treated with ribavirin.

29 Ten received toclizumab and/or ribavirin; 1 received remdesivir.

30 0 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day; Panel 2-Arm 2 (n = 9; GT1b):

31 and 311 receiving ledipasvir-sofosbuvir plus ribavirin (212 for 12 weeks and 81 for 24 weeks, 18 for

32 tonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions).

33 e prevalent in treatment regimens containing ribavirin (46%, 95% CI 33-59%) compared to ribavirin-fre

34 Through this pathway, the antiviral compound ribavirin 5'-monophosphate is significantly incorporated

35 asvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin (6%).

36 seltamivir (75 mg), amantadine (100 mg), and ribavirin (600 mg) combination therapy or oseltamivir mo

37 ype 2 infection (treated with sofosbuvir and ribavirin), 74.8% (95% CI, 72.2%-77.3%) of those with ge

38 treated with sofosbuvir (SOF)/ledipasvir +/- ribavirin (85%) followed by SOF + daclatasvir +/- ribavi

39 in patients given ledipasvir/sofosbuvir plus ribavirin, 87.0% in patients given sofosbuvir and pegyla

40 neteen participants commenced sofosbuvir and ribavirin (89% male, 74% with human immunodeficiency vir

41 irin (85%) followed by SOF + daclatasvir +/- ribavirin (9%) and ombitasvir/paritaprevir/ritonavir + d

42 of patients received LDV/SOF with or without ribavirin (91%) and were treated for 12 weeks.

43 Treatment options include administration of ribavirin, a purine analog, although the mechanism of it

44 elbasvir for 12 or 16 weeks, with or without ribavirin, achieved high cure rates and had an excellent

45 atasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did

46 ose combination of ledipasvir/sofosbuvir +/- ribavirin administered for 8, 12, or 24 weeks in patient

47 ction of immunosuppressive treatment as well ribavirin alone for 4 months did not result in viral cle

48 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin and 4/8 (50%) GT1b without ribavirin patients,

49 esistant to the mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the WT virus, whereas

50 ons, mutagenic nucleoside analogues, such as ribavirin and 5-fluorouracil, have been ineffective at i

51 st human cases treated with a combination of ribavirin and favipiravir.

52 Treatment was targeted against hepatitis C (ribavirin and interferon) in addition to immunosuppressi

53 tion of simeprevir + TMC647055/ritonavir +/- ribavirin and of the 3-DAA combination of simeprevir + T

54 of this study was to evaluate the effect of ribavirin and recombinant interferon (RBV/rIFN) therapy

55 HCV infection is based on interferon-alpha, ribavirin and the new direct-acting antivirals (DAAs), s

56 and 70.6% of patients given sofosbuvir plus ribavirin), and 89.6% (95% CI 82.8%-93.9%) of those with

57 ven sofosbuvir and pegylated-interferon plus ribavirin, and 70.6% of patients given sofosbuvir plus r

58 by sofosbuvir plus pegylated interferon and ribavirin, and all-oral therapies where available, but c

59 fluence the outcome of retreatment with SOF, ribavirin, and pegylated interferon.

60 reated with combination pegylated IFN-alpha, ribavirin, and telaprevir/boceprevir.

61 4-week no ribavirin arm and the 16-week plus ribavirin arm (lost to follow-up, n = 1), respectively.

62 enotype (GT)1 participants in the 24-week no ribavirin arm and the 16-week plus ribavirin arm (lost t

63 suggesting promise in EIF4E targeting using ribavirin as a means of treatment.

64 ct-acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in s

65 d during retreatment, 1 patient discontinued ribavirin because of pruritus.

66 perspective, HCV therapy using LDV/SOF with ribavirin before LT is the most cost-effective strategy

67 We used serial passage in ribavirin, beginning with a variety of ribavirin-sensiti

68 Ribavirin causes nuclear EIF4E to re-localize to the cyt

69 treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causin

70 .7%) were associated with more relapse after ribavirin cessation.

71 s who achieved SVR vs those who relapsed was ribavirin concentration at the end of treatment.

72 verse events occurred more frequently in the ribavirin-containing arms of the studies.

73 Ribavirin cooperates with chemotherapy, particularly L-a

74 eek regimen of elbasvir and grazoprevir plus ribavirin could increase efficacy in patients with HCV g

75 avir/ombitasvir, dasabuvir (twice daily) +/- ribavirin (D3FEAT) for 12 weeks administered in electron

76 navir/ombitasvir, dasabuvir (twice-daily) +/-ribavirin (D3FEAT) for 12 weeks administered in electron

77 itaprevir/ritonavir/dasabuvir/ombitasvir +/- ribavirin (D3FEAT) for 12 weeks and completed behavioral

78 rm treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunodeficiency

79 of elbasvir and grazoprevir, with or without ribavirin, demonstrated high rates of sustained virologi

80 The addition of ribavirin did not appear to increase SVR12 but was assoc

81 merase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearanc

82 Ribavirin did not influence SVR rates and was more often

83 fe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was

84 regimens (pegylated interferon alpha 2b and ribavirin different dosages, and long-term treatment wit

85 0 mg ritonavir once daily, with weight-based ribavirin dosed twice daily for either 12 weeks or 16 we

86 For all patients, ribavirin dosing was determined by baseline weight (up t

87 grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and

88 tients who received pegylated interferon and ribavirin during 2004-2013 were followed until December

89 In addition, we tested ribavirin efficacy in vivo, alone and in combination wit

90 inical responses to the m(7)G-cap competitor ribavirin, eIF4E is mainly cytoplasmic.

91 the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits.

92 ross infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effect

93 Inhibition of IMPDH2 activity with ribavirin favors ANKRD9 binding to IMPDH2 rods.

94 857 (100 mg) once daily for 6-12 weeks, plus ribavirin for 1 treatment group consisting of treatment-

95 ho were treated with EBR/GZR with or without ribavirin for 12 or 16 weeks.

96 tide analogue NS5B polymerase inhibitor) +/- ribavirin for 12 or 24 weeks in HCV genotype (GT)1-infec

97 d patients receiving simeprevir+sofosbuvir+/-ribavirin for 12 or 24 weeks.

98 mly assigned to groups that received G/P and ribavirin for 12 weeks (n = 21, group C) or G/P for 16 w

99 Ombitasvir, paritaprevir, and ritonavir plus ribavirin for 12 weeks achieved SVR12 in a high proporti

100 fosbuvir plus ledipasvir, or sofosbuvir plus ribavirin for 12 weeks are all suitable.

101 for 24 weeks or sofosbuvir, daclatasvir, and ribavirin for 12 weeks are the optimal oral therapies, p

102 Sofosbuvir-ribavirin for 12 weeks for the treatment of acute HCV ge

103 d the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to <12 years c

104 hereas sofosbuvir, pegylated interferon, and ribavirin for 12 weeks is an alternative regimen.

105 Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV suppression for at

106 osbuvir (90 mg and 400 mg) plus weight-based ribavirin for 12 weeks.

107 ligible for retreatment with EBR/GZR+SOF and ribavirin for 12 weeks.

108 en ledipasvir/sofosbuvir in combination with ribavirin for 12 weeks.

109 Sofosbuvir and ribavirin for 12-24 weeks is safe and well tolerated in

110 rifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks.

111 cruited before treatment with interferon and ribavirin for 24 to 48 weeks, according to HCV genotype.

112 acy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus

113 d therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was well tolerated and effective,

114 herapy (21 patients received sofosbuvir plus ribavirin for 24 weeks, 4 patients received sofosbuvir p

115 was to assess the efficacy of sofosbuvir and ribavirin for 6 weeks in individuals with recent HCV inf

116 ination of sofosbuvir and ledipasvir without ribavirin for 8 or 12 weeks.

117 and efficacy of 12 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV infection in pa

118 eks of ledipasvir/sofosbuvir with or without ribavirin for the treatment of treatment-naive and treat

119 evir, and ritonavir, plus dasabuvir, without ribavirin, for 12 weeks.

120 ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effect

121 evir, and ritonavir, plus dasabuvir, without ribavirin, for 8 weeks was efficacious and well tolerate

122 is study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/

123 e safety and efficacy of the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney t

124 e safety and efficacy of the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney t

125 nd tolerance of an all-oral, interferon- and ribavirin-free regimen of sofosbuvir plus daclatasvir in

126 g ribavirin (46%, 95% CI 33-59%) compared to ribavirin-free regimens (3%, 95% CI 0-9%).

127 Furthermore, the interferon- and ribavirin-free SOF/VEL regimen resulted in a rapid impro

128 , efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose com

129 The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral re

130 who were treated with DAAs, with or without ribavirin, from 2014 through 2016 (129 patients achieved

131 general population); regimens that included ribavirin had more mild or moderate adverse events than

132 The addition of ribavirin had no detectable effects on SVR.

133 Sofosbuvir/ribavirin had the lowest risk to cause a potentially sig

134 Pegylated interferon plus ribavirin has been replaced by sofosbuvir plus pegylated

135 Ribavirin has been used, but case studies show no impact

136 fosbuvir with ledipasvir and sofosbuvir with ribavirin have received regulatory approval and guidelin

137 Treatment with pegylated interferon and ribavirin (hazard ratio 0.78; 95% CI 0.71-0.85) or a DAA

138 In the absence of ribavirin, HRSV-specific transcripts accounted for up to

139 sbuvir/velpatasvir (n = 57), with or without ribavirin in 12 centers across Thailand to estimate sust

140 d the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 with hepatitis C vir

141 of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patient

142 of oral RBV as a safe alternative to inhaled ribavirin in LTRs.

143 evir, and ritonavir, plus dasabuvir, without ribavirin in patients infected with HCV genotype 1b with

144 d efficacy of ledipasvir and sofosbuvir plus ribavirin in patients with genotype 3 HCV infection.

145 ase inhibitor; co-dosed with ritonavir) plus ribavirin in patients with HCV genotype 4 infection and

146 tasvir plus dasabuvir (PrOD) with or without ribavirin in persons with HCV-1/HIV coinfection suppress

147 rotease inhibitor dosed with ritonavir, plus ribavirin in treatment of chronic HCV infection in Egypt

148 nd the NS5A inhibitor elbasvir together with ribavirin in treatment-experienced patients with chronic

149 sis who had failed pegylated interferon plus ribavirin, in 25 of 28 (89%) patients with HCV genotype

150 ere dosed for 12 or 24 weeks with or without ribavirin, in line with existing guidelines.

151 ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibi

152 y of 12 and 16 weeks of G/P, with or without ribavirin, in patients with HCV genotype 1 infection wit

153 f ledipasvir and sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 infection.

154 Ribavirin increased adverse events but did not increase

155 ent viral RNA recombination, confirming that ribavirin-induced error catastrophe coincides with defec

156 lymerase and rendered the virus resistant to ribavirin-induced error catastrophe, but only when RNA r

157 sexual RNA replication mechanisms counteract ribavirin-induced error catastrophe, we selected for rib

158 inhibited RNA recombination and exacerbated ribavirin-induced error catastrophe.

159 bination is required for poliovirus to evade ribavirin-induced error catastrophe.

160 Our work showed that ribavirin inhibits glioma cell growth and migration, and

161 However, ribavirin is associated with hemolytic events and is poo

162 Ribavirin is currently recommended for treating chronic

163 id organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepat

164 arge-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV i

165 gylated interferon alpha 2a or alpha 2b plus ribavirin is more cost-effective than a palliative care

166 of elbasvir and grazoprevir, with or without ribavirin is safe and effective for patients with HCV ge

167 Long-term treatment with ribavirin is safe in liver transplant recipients, withou

168 Ribavirin is the only antiviral treatment option for non

169 Ribavirin is used as an experimental therapy with other

170 ess of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF +/- RBV) and ombitasvir/ paritaprevir

171 Oral ribavirin may be an effective alternative to aerosolized

172 ents with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predict

173 Ribavirin monotherapy and a minimization of immunosuppre

174 ferent dosages, and long-term treatment with ribavirin monotherapy still ongoing) but without achievi

175 etectable in the serum and stools throughout ribavirin monotherapy.

176 ith HCV genotype 1a infections also received ribavirin (n = 13), whereas those with genotype 1b infec

177 Here, we report the effect of ribavirin on proliferation, cell cycle, cell death and m

178 ction of immunosuppression or treatment with ribavirin or pegylated interferon-alpha can result in vi

179 prior interferon or pegylated interferon +/- ribavirin or sofosbuvir plus ribavirin +/- pegylated int

180 eron or pegylated interferon with or without ribavirin, or sofosbuvir plus ribavirin with or without

181 nt had a serious adverse event of accidental ribavirin overdose requiring hospitalization for monitor

182 g + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 75 mg + TMC647055 600 mg/

183 GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4: simeprevir 75 mg + TMC647055 450 mg/

184 nel 2-Arm 1, 5/10 and 6/12 (50%) GT1a/GT1b + ribavirin patients achieved SVR12, versus 3/9 (33%) GT1b

185 chieved SVR12, versus 3/9 (33%) GT1b without ribavirin patients in Panel 2-Arm 2.

186 GT1a + ribavirin and 4/8 (50%) GT1b without ribavirin patients, respectively, achieved SVR12.

187 ntrols treated with pegylated interferon and ribavirin; patients with glomerulonephritis experienced

188 V therapy comprised pegylated interferon and ribavirin (PegIFN-RBV) plus one direct-acting antiviral

189 interferon +/- ribavirin or sofosbuvir plus ribavirin +/- pegylated interferon therapy) patients wit

190 with >/= 4 weeks of pegylated interferon and ribavirin plus either boceprevir, telaprevir, or simepre

191 Indeed, m(7)G cap analogs or ribavirin prevents nuclear entry of eIF4E, which mirrors

192 Ledipasvir-sofosbuvir and ribavirin provided high rates of SVR12 for patients with

193 We evaluated the antiviral activities of ribavirin (RBV) and interferon (IFN) alfa as monotherapy

194 s (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks.

195 vir-velpatasvir-voxilaprevir with or without ribavirin (RBV) for 12 weeks.

196 llowing strategies: peg-interferon (PEG-IFN)/ribavirin (RBV) for 48 weeks, PEG-IFN/RBV plus boceprevi

197 The use of oral ribavirin (RBV) for respiratory syncytial virus (RSV) in

198 Ribavirin (RBV) has been used to treat RSV-infected LTRs

199 fety of ABT-493 plus ABT-530 with or without ribavirin (RBV) in GT1- or GT3-infected patients with co

200 f glecaprevir (GLE) + pibrentasvir (PIB) +/- ribavirin (RBV) in HCV genotype 1-infected patients with

201 tained virologic response (SVR) of LDV/SOF+/-ribavirin (RBV) in routine medical practice.

202 LLY-3+ study (N = 50) evaluated DCV-SOF with ribavirin (RBV) in treatment-naive (n = 13) or treatment

203 tonavir with dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV)

204 Sofosbuvir (SOF) + daclatasvir +/- ribavirin (RBV) was used in 123 patients, SOF + RBV in 3

205 This shift was blocked by ribavirin (RBV), an antiviral drug that reduces relapse

206 imeprevir (SMV)/SOF, 94% (16/17) for SMV/SOF/ribavirin (RBV), and 52% (16/31) for SOF/RBV.

207 d patients treated with interferon (IFN) and ribavirin (RBV), between 2000 and 2008.

208 on SOF-based regimens (SOF + simeprevir +/- ribavirin (RBV), n = 53; SOF + pegylated interferon + RB

209 DCV) plus pegylated interferon (Peg-IFN) and ribavirin (RBV), with (n = 3) or without (n = 13) asunap

210 /ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV).

211 nce daily for 12 to 24 weeks with or without ribavirin (RBV).

212 ter liver transplantation include the use of ribavirin (RBV).

213 eatment regimens used were: Sofosbuvir (SOF)/ribavirin (RBV)/pegylated interferon (PEG-IFN), 25.2%; S

214 igallocatechin gallate (EGCG) 400 mg without ribavirin (RBV); and Dactavira plus, which includes RBV

215 been treated with a pegylated interferon and ribavirin regimen (n = 4436) or a DAA-containing regimen

216 hose treated with a pegylated interferon and ribavirin regimen (PEG/RBV, n = 4764) or a DAA-containin

217 up treated with the pegylated interferon and ribavirin regimen, 16.3 per 1000 patient-years (95% CI 1

218 gylated interferon-alpha (Peg-IFN-alpha) and ribavirin regimens.

219 y mild, with the exception of 1 patient with ribavirin-related anemia requiring blood transfusion.

220 the basis of these results, we propose that ribavirin represents a new therapeutic option for gliobl

221 r SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood t

222 Ribavirin resistance G64S mutations were selected in two

223 ected in two independent lineages, and novel ribavirin resistance mutations were selected in the poly

224 and W237L(LF) mutant viruses exhibited lower ribavirin resistance.

225 suggesting that recombination contributes to ribavirin resistance.

226 on and that RNA recombination contributes to ribavirin resistance.

227 s used to inhibit emergence of G64S-mediated ribavirin resistance.

228 Ribavirin-resistant mutants reemerged by escaping lethal

229 In the present study, these ribavirin-resistant mutants were evaluated in terms of t

230 sequently, in the present study, both of the ribavirin-resistant mutants were evaluated in terms of t

231 ng with a variety of ribavirin-sensitive and ribavirin-resistant parental viruses.

232 n-induced error catastrophe, we selected for ribavirin-resistant poliovirus to identify polymerase re

233 In a previous study, ribavirin-resistant porcine reproductive and respiratory

234 In a previous study, two ribavirin-resistant PRRSV mutants (RVRp13 and RVRp22) we

235 ontained an L420A polymerase mutation, while ribavirin-resistant virus contained a G64S polymerase mu

236 A similar regimen with ribavirin resulted in a temporary decrease in PROs, whic

237 l and endo-norbornyladenosines but increased ribavirin selectivity.

238 ge in ribavirin, beginning with a variety of ribavirin-sensitive and ribavirin-resistant parental vir

239 In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11

240 Ribavirin-sensitive virus contained an L420A polymerase

241 han the wild type (WT) and display decreased ribavirin sensitivity compared to the WT.

242 376K) exhibited divergent RNA recombination, ribavirin sensitivity, and biochemical phenotypes, consi

243 Ribavirin slows increases in peripheral blasts in KMT2A-

244 6, sofosbuvir plus pegylated interferon and ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plu

245 ent with interferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medicat

246 virus more susceptible to the antiviral drug ribavirin, suggesting that recombination contributes to

247 al therapy is limited to an off-label use of ribavirin that is only partially effective.

248 revir/ritonavir, ombitasvir, dasabuvir, with ribavirin) that enrolled chronic genotype 1a HCV-infecte

249 Ribavirin, the only clinically approved drug known to ta

250 After a first course of ribavirin, the SVR rate was 81.2%.

251 Ribavirin therapy was given to a subset of the patients.

252 Ribavirin therapy was interrupted in 9 patients due to a

253 Ribavirin therapy was tried but no evidence for its bene

254 Ribavirin therapy was tried but no evidence for its bene

255 of chronically infected patients undergoing ribavirin therapy.

256 thout concomitant pegylated interferon-alpha/ribavirin therapy.

257 Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infec

258 Background: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infec

259 on SVR reported for pegylated interferon and ribavirin) to achieve superiority.

260 t is only with pegylated interferon and oral ribavirin) to investigate the effect of DAA use.

261 ons of fecal specimens from HEV-infected and ribavirin-treated humanized mice were analyzed using HEV

262 ble for >100 days after HEV RNA clearance in ribavirin-treated patients with chronic HEV.

263 Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-de

264 tment responses to pegylated interferon plus ribavirin treatment (PegIFN/RBV) have not been fully ill

265 atified by previous pegylated interferon and ribavirin treatment experience using a web-based interac

266 We also demonstrate that ribavirin treatment in combination with temozolomide or

267 Finally and most importantly, ribavirin treatment in vivo significantly enhances chemo

268 with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIR

269 We find that ribavirin treatment of actively dividing infant ALL cell

270 Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant

271 Ribavirin treatment resulted in a >90% reduction in abun

272 e and interferon or pegylated interferon and ribavirin treatment-experienced patients with HCV genoty

273 enrolled treatment-naive and interferon (+/-ribavirin) treatment-experienced patients with HCV GT1,

274 11 to 50 of P and formally demonstrate that ribavirin triphosphate (RTP) inhibits the RdRP.

275 ofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotyp

276 once daily coadministered with weight-based ribavirin twice daily for 12 weeks in genotype 1-infecte

277 svir/sofosbuvir) once daily, with or without ribavirin twice daily.

278 Treatment with interferon and ribavirin upregulated beta-defensin-1, but not other bet

279 ics, use of antidepressants, use of opioids, ribavirin use, the presence of ascites, encephalopathy,

280 combination of oseltamivir, amantadine, and ribavirin versus oseltamivir monotherapy with matching p

281 R12 for the 16-week regimen with and without ribavirin was achieved in 26 (100% [95% CI 87-100]) of 2

282 R12 for the 12-week regimen with and without ribavirin was achieved in 28 (97% [95% CI 82-100]) of 29

283 ruzasvir, and uprifosbuvir with and without ribavirin was achieved in 39 (93% [95% CI 81-99]) of 42

284 R12 for the 12-week regimen with and without ribavirin was achieved in 87 (99% [95% CI 94-100]) of 88

285 The addition of ribavirin was associated with increased SVR rates for ce

286 gylated interferon alpha 2a or alpha 2b plus ribavirin was dominant or cost-saving in Thailand compar

287 Ribavirin was given at the median dose of 600 (range, 29

288 Sofosbuvir and ribavirin was safe and highly effective in adolescents w

289 Six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was

290 Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly effective in chi

291 imeprevir or sofosbuvir/pegylated interferon/ribavirin, was included for comparison.

292 A 5'-diphosphate form of antiviral ribavirin weakly inhibited the GpppA formation but did n

293 targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E

294 nfections is limited to the off-label use of ribavirin, which is partially effective and associated w

295 ith or without ribavirin, or sofosbuvir plus ribavirin with or without pegylated interferon.

296 ved for prophylaxis in high-risk infants and ribavirin with very limited efficacy and significant saf

297 ion who had been treated with sofosbuvir and ribavirin, with or without pegylated interferon.

298 ed response to treatment with sofosbuvir and ribavirin, with or without pegylated interferon.

299 ailed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir

300 tional therapy with pegylated interferon and ribavirin yields approximately 40% sustained virologic r